Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • COVID-19
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Editors' Blog
    • Email Alerts
  • Info For
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • About
    • The JABFM
    • Editorial Board
    • Indexing
  • Classifieds
  • More
    • Email Alerts
    • Feedback
    • ABFM News
    • Folders
    • Help
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • Home
  • Articles
    • Current Issue
    • COVID-19
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Editors' Blog
    • Email Alerts
  • Info For
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • About
    • The JABFM
    • Editorial Board
    • Indexing
  • Classifieds
  • More
    • Email Alerts
    • Feedback
    • ABFM News
    • Folders
    • Help
  • JABFM On Twitter
  • JABFM On YouTube
  • JABFM On Facebook
Brief ReportBrief Report

The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency

Victoria Boggiano, Courtenay Gilmore Wilson, E. Blake Fagan, Julienne Kirk, Kelly Bossenbroek-Fedoriw and Casey R. Tak
The Journal of the American Board of Family Medicine November 2020, 33 (6) 998-1003; DOI: https://doi.org/10.3122/jabfm.2020.06.200127
Victoria Boggiano
the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtenay Gilmore Wilson
the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Blake Fagan
the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julienne Kirk
the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Bossenbroek-Fedoriw
the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Casey R. Tak
the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 33 no. 6 998-1003
DOI 
https://doi.org/10.3122/jabfm.2020.06.200127
PubMed 
33219079

Published By 
The Journal of the American Board of Family Medicine
Print ISSN 
1557-2625
Online ISSN 
1558-7118
History 
  • Received for publication April 8, 2020
  • Revision received June 3, 2020
  • Accepted for publication June 4, 2020
  • Published online November 20, 2020.

Copyright & Usage 
© Copyright 2020 by the American Board of Family Medicine.

Author Information

  1. Victoria Boggiano, MD, MPH,
  2. Courtenay Gilmore Wilson, PharmD, BCACP, CPP,
  3. E. Blake Fagan, MD,
  4. Julienne Kirk, PharmD,
  5. Kelly Bossenbroek-Fedoriw, MD and
  6. Casey R. Tak, PhD, MPH
  1. From the Department of Family Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill (VB, CGW, EBF, KBF); UNC Health Sciences at MAHEC, Asheville, NC (CGW, EBF, CRT); Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill (CGW); Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (JK); Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC (CRT)
  1. Corresponding author: Courtenay Gilmore Wilson, PharmD, BCACP, CPP, 123 Hendersonville Rd, Asheville, NC 28803 (E-mail: courtenay.wilson{at}mahec.net).
View Full Text

Cited By...

  • 1 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 33 (6)
The Journal of the American Board of Family Medicine
Vol. 33, Issue 6
November-December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency
Victoria Boggiano, Courtenay Gilmore Wilson, E. Blake Fagan, Julienne Kirk, Kelly Bossenbroek-Fedoriw, Casey R. Tak
The Journal of the American Board of Family Medicine Nov 2020, 33 (6) 998-1003; DOI: 10.3122/jabfm.2020.06.200127

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency
Victoria Boggiano, Courtenay Gilmore Wilson, E. Blake Fagan, Julienne Kirk, Kelly Bossenbroek-Fedoriw, Casey R. Tak
The Journal of the American Board of Family Medicine Nov 2020, 33 (6) 998-1003; DOI: 10.3122/jabfm.2020.06.200127
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Notes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Must-Read Family Medicine Research--Glucosamine/Chondroitin Supplements and Mortality, Telomere Length and the Doctor-Patient Relationship, Reducing Opioid Use, and More
  • Google Scholar

More in this TOC Section

  • Screening for Diabetic Retinopathy with a Nonmydriatic Ultra-Wide-Field Retina Camera by Family Medicine Physicians
  • Association of Prediabetes Status Awareness With Behaviors and Perception of Health
  • Provision of Early Pregnancy Loss Care in New York Federally Qualified Health Centers
Show more Brief Report

Similar Articles

Keywords

  • Buprenorphine
  • Family Medicine
  • Health Services Accessibility
  • Health Workforce
  • Opioid-Related Disorders
  • Primary Health Care
  • Residency
  • Surveys and Questionnaires

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us

© 2021 American Board of Family Medicine

Powered by HighWire